In bacterial infections, PERK inhibition may serve dual therapeutic purposes by preventing pathogen‐induced translational shutdown that impairs host immune protein synthesis and by disrupting bacterial exploitation of PERK signaling pathways to establish replication niches. The gene discussed is EIF2AK3; the disease is bacterial infectious disease.